Biosimilars – Corporate Strategies – Biosimilar Profiles
The development and commercialization of biosimilars require a significant investment in capital, resources, and time. Biosimilar developers must ensure that they are equipped with the necessary expertise in development and manufacturing capabilities. With the number of approved biosimilars ever increasing, the biopharmaceutical space is set to become more competitive for both innovator and biosimilar companies. As such, it is paramount that biosimilar and innovator companies have well-defined strategies to maximize their competitiveness. In this content, we assess strategies—based on actual practices—that companies can use to flourish in competitive global markets.
The product profiles of the biosimilars that have launched or will soon enter the major markets (United States, EU, and Japan) are included in the section “Biosimilar Profiles”. These profiles include information about the biosimilar developer(s) and marketer(s), regulatory timelines, development history, approved indications, summary of clinical development, and position in the market.
Questions answered in this report:
- How have biosimilar developers achieved success in the biosimilars market?
- What options are available to biosimilar developers that lack in-house manufacturing capabilities?
- What factors should biosimilar developers consider when designing biosimilar clinical programs?
- How can biosimilar and reference-brand companies exploit the multifactorial decision-making process used by stakeholders to differentiate their product from the competition?
- What types of data do physicians require to increase their use of biosimilars in biologic-treated patients?
- What options are available to reference-brand companies seeking to defend against biosimilar entry?
Key markets covered:
- Global
Key companies mentioned:
- AbbVie
- Amgen
- Biocon
- Biogen
- Boehringer Ingelheim
- Celltrion
- Coherus Biosciences
- Eli Lilly
- Fresenius Kabi
- Grasustek
- Halozyme
- Hospira
- Merck & Co.
- Mundipharma
- Mylan
- Novartis
- Pfizer
- Roche
- Samsung Bioepis
- Sandoz
- Sanofi
- Teva
Key drugs mentioned:
- Abasaglar/Basaglar
- Admelog/Insulin Lispro Sanofi
- Amjevita/Amgevita/Solymbic
- Avastin
- Avsola
- Benepali
- Binocrit
- Cyltezo
- Enbrel
- Erelzi
- Flixabi
- Fulphila
- Herceptin
- Herzuma
- Humira
- Hulio
- Hyrimoz
- Idacio
- Imraldi/Hadlima
- Inflectra
- Infliximab BS IV Infusion
- Kanjinti
- Mvasi
- Nepexto
- Neulasta
- Nivestim
- Ogrivi
- Ontruzant
- Pelgraz
- Pelmeg
- Remicade
- Remsima
- Renflexis
- Rituxan/MabThera
- Rixathon/Riximyo
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Zarzio/Zarxio
- Zercepac
- Zessly
- Ziextenzo
- Zirabev
Anushree Dhar, M.Sc., is an analyst on the Biosimilars team at Clarivate. She has several years of experience working in competitive intelligence, medical, and pharmaceutical syndicated research. Prior to joining Clarivate, she was a senior consultant at TheraTraQ, where she was involved in biosimilar and CNS projects for global pharmaceutical clients. Ms. Dhar also worked as an industry analyst at Technavio, part of Infiniti Research, where she worked on various syndicated research reports, conducted primary and secondary research, and prepared reports on clinical trials. Ms. Dhar earned her M.Sc. degree in biotechnology at Bangalore University.